Navacaprant
Major Depressive Episode Associated With Bipolar II Disorder
Neumora Therapeutics, Inc.Small moleculePhase 2Active
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
21 Active assets in the Major Depressive Episode Associated With Bipolar II Disorder cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Lurasidone Massachusetts General Hospital | Phase 4 | BBB |
Valproic Acid National Cheng-Kung University Hospital | Phase 4 | BB |
Seroquel® First Affiliated Hospital of Zhejiang University | Phase 4 | BB |
VENLOR Stanley Medical Research Institute | Phase 4 | BB |
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE Joshua Rosenblat | Phase 4 | BB |
View all 37 →
Same molecule, other indications
Navacaprant is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →